Roswell Park Comprehensive Cancer Center is a cancer research and treatment center located in Buffalo, New York. Founded by surgeon Roswell Park in 1898, the center was the first in the United States to specifically focus on cancer research. The center is usually called Roswell Park in short. The center, which conducts clinical research on cancer as well as the development new drugs, provides advanced treatment for all forms of adult and pediatric cancer, and serves as a member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center is as of 2019, the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center".
Bernadine Patricia Healy was an American cardiologist and the first female director of the National Institutes of Health (NIH).
The Duke University School of Medicine, commonly known as Duke Med, is the medical school of Duke University. It is located in the Collegiate Gothic-style West Campus of Duke University in Durham, North Carolina. The School of Medicine, along with the Duke University School of Nursing, Duke University Hospital, Duke Regional Hospital, Duke Children's Hospital, Duke Raleigh Hospital, and other affiliated hospitals, clinics, and laboratories, make up the Duke University Health System. Established in 1925 by James B. Duke, the School of Medicine has earned its reputation as an integral part of one of the world's foremost patient care and biomedical research institutions.
The State University of New York Upstate Medical University is a public medical school in Syracuse, New York. Founded in 1834, Upstate is the 15th oldest medical school in the United States and is the only medical school in Central New York. The university is part of the State University of New York (SUNY) system.
The International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers. The ICGC was launched in 2008 to coordinate large-scale cancer genome studies in tumours from 50 cancer types and/or subtypes that are of main importance across the globe.
The UPMC Hillman Cancer Center, previously the University of Pittsburgh Cancer Institute (UPCI), is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center located in the Hillman Cancer Center in the Shadyside neighborhood of Pittsburgh, adjacent to UPMC Shadyside. The only NCI-designated cancer center in Western Pennsylvania, Hillman is composed of collaborative academic and research efforts between the University of Pittsburgh, the University of Pittsburgh Medical Center (UPMC), and Carnegie Mellon University. Hillman provides clinical cancer care to some 74,000 patients treated at its facilities at both the Hillman Cancer Center location in the Shadyside neighborhood of Pittsburgh and at UPMC-affiliated sites throughout Pennsylvania, New York, Ohio, and overseas locations. Founded in 1984, Hillman became the youngest cancer center in history to achieve NCI-designation. As of 2007, Hillman had received nearly $200 million in funding from the National Cancer Institute, which ranks it as one of the top ten cancer research institutes.
Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.
Alan D. D'Andrea is an American cancer researcher and the Fuller American Cancer Society Professor of Radiation Oncology at Harvard Medical School. D'Andrea's research at the Dana Farber Cancer Institute focuses on chromosome instability and cancer susceptibility. He is currently the director of the Center for DNA Damage and Repair and the director of the Susan F. Smith Center for Women's Cancer.
The Max Planck Florida Institute for Neuroscience (MPFI), is a research facility located in Jupiter, Florida. Its research focuses on brain function and neural circuits, using techniques to visualize microscopic molecular processes. It is the first institute established by the Max Planck Society in North America.
Timothy Joseph Yeatman, M.D. F.A.C.S. is currently the Associate Center Director for Translational Research and Innovation for the Tampa General Hospital Cancer Institute and Professor of Surgery at the University of South Florida, United States. He previously served as the Executive Medical Director of Oncologic Services and the Senior Medical Director for the Oncology Clinical Program at Intermountain Healthcare, serving 23 hospitals and >6000 patients across the State of Utah and beyond. He was also Professor of Surgery at the University of Utah and a Member of the Huntsman Cancer Institute’s Cellular Response and Regulation Program. Dr Yeatman was also the Director of Gibbs Cancer Center and President of Gibbs Cancer Center & Research Institute in Spartanburg, South Carolinawhere he founded the Guardian Research Network, a novel approach to Clincial data analytics, leveraging the entire EHR for real time database queries for identifying clinical trial candidates. Yeatman held numerous positions at the Moffitt Cancer Center (MCC) in Florida over a 20 year span from 1992 - 2012. Yeatman served as the Associate Center Director for Clinical Investigations, the Associate Center Director for Translational Research, the Executive Vice President for Translational Research, Professor of Surgery and Cncologic Sciences, and the GI Tumor Program Leader at the Moffitt Cancer Center and the University of South Florida. There he led a $100m Moffitt:Merck collaboration and co-founded a novel biotech company, M2Gen. He also served as Chief Scientific Officer for the Center for Advancement of Science in Space (CASIS), a non-profit organization appointed by Congress and funded by NASA to oversee all scientific use of the International Space Station. He has been funded by the National Cancer Institute (NCI) since 1993 and continues to perform basic and translational colorectal cancer research in genomics and biomarker development.
Dr. Matthias Gromeier is a Professor in the Department of Neurosurgery at Duke University Medical Center, who has developed a way to re-engineer a poliovirus to inspire the human immune system to kill cancer cells in a specific set of cancers. The re-engineered virus, called PVSRIPO, cannot replicate itself in normal cells, but can replicate itself in cancer cells that have an overabundance of the protein marker that the poliovirus targets.
PVSRIPO, or PVS-RIPO, is the name of a modified polio virus that has recently shown promise for treating cancer. It is the focus of clinical trials being conducted at Duke University.
Samuel Achilefu is a Nigerian-born scientist and medical researcher who has pioneered both fundamental and applied research in science, engineering, and medicine. Dr. Samuel Achilefu is the Michel M. Ter-Pogossian Professor of Radiology and Vice Chair for Innovation and Entrepreneurship at the Mallinckrodt Institute of Radiology, Washington University School of Medicine. He holds joint appointments as a professor of medicine, biochemistry and molecular biophysics, and biomedical engineering. He currently serves as the Director of the Washington University Molecular Imaging Center and the privately funded Theranostic Innovation Program. He is co-director of the Center for Multiple Myeloma Nanotherapy and co-Leader of the Oncologic Imaging Program of the Alvin J. Siteman Cancer Center at Washington University.
Viviane Tabar is an American neurosurgeon, the Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center in New York since 2017.
Peter Edward Fecci is an American neurosurgeon, professor and researcher. He is an Associate Professor of Neurosurgery, Pathology and Immunology at Duke University School of Medicine. He also serves as Director of the Duke Center for Brain and Spine Metastasis, Director of the Brain Tumor Immunotherapy Program, Residency Program Director, and Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke.
Paul J. Tesar is an American developmental biologist. He is the Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics at Case Western Reserve University School of Medicine. His research is focused on regenerative medicine.
Duane A. Mitchell is an American physician-scientist and university professor. He is currently employed at the University of Florida College of Medicine, in Gainesville, Florida as the Assistant Vice President for Research, Associate Dean for Translational Science and Clinical Research, and Director of the University of Florida (UF) Clinical and Translational Science Institute. He is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery. and Co-Director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy. Mitchell is also the founder, President, and Chairman of iOncologi, Inc., a biotechnology company in Gainesville, FL specializing in immuno-oncology.
Laurence Zitvogel is a French physician specializing in oncology and immunology with a large research experience in exosomes and the biological impact of those structures in malignant neoplasms.
Pamela Sumiko Ohashi, PhD, FRSC is a Canadian medical researcher. She is co-director of the Campbell Family Institute for Breast Cancer Research, director of the Cancer Immune Therapy Program at the Princess Margaret Cancer Centre and a professor at the University of Toronto.
Raul Gainetdinov is a pharmacologist and neuroscientist. The main direction of his research is psychiatric and neurological diseases of the brain, such as schizophrenia, ADHD, depression and Parkinson's disease. He is the author of fundamental scientific works in pharmacology of dopamine, β-Arrestins and NMDA receptors. He is a pioneer researcher of Trace amine-associated receptors.
